Wang Wenjian, 1992, graduated from Southern Anhui Medical College with a bachelor's degree. 1992- 1999, stayed in school to teach, and served as a nephrologist, attending physician and lecturer in the affiliated Yijishan Hospital. 1999-2004 Postgraduate in Department of Nephrology, First Affiliated Hospital of Sun Yat-sen University (Clinical Key Laboratory of Ministry of Education and Ministry of Health, State Key Discipline) (received the doctor's degree of medicine in advance 1 year, and won the South Guangdong Excellent Postgraduate Award twice during the period). Since 2004, he has worked in the Department of Nephrology (National Key Clinical College) of Guangdong Provincial People's Hospital. In 2006, he was promoted to deputy chief physician, associate professor and master tutor. From 2008 to 2065438+00, he was sent to the Department of Nephrology, Baylor Medical College for postdoctoral research on diabetic nephropathy. 20 12 12 was promoted to chief physician and professor.
Wang Wenjian has successively presided over two national natural science funds and two Guangdong natural science funds, and participated in NIH Fund 10, with a total research funding of more than 2 million yuan. Important discoveries have been made in the mechanism of lipid kidney injury and diabetic nephropathy, and the transgenic mouse model of ROCK 1db/db mice and podocyte-specific conditional expression activity ROCK 1 was pioneered. He has published 47 papers in international authoritative magazines such as Cell Metabolism, Kidney International and Journal of Biochemistry, with a cumulative impact factor of 62.606 (the highest impact factor of the first author 18.207), and the papers have been cited by SCI for 200 times, reviewed by the third party 1 article, and edited 3 monographs such as IgA Nephropathy as deputy editor. Won the third prize of Guangdong Science and Technology Progress Award. Won 2 national invention patents.
Director Wang Wenjian is good at the diagnosis and treatment of difficult renal diseases such as acute and chronic renal failure, acute and chronic glomerulonephritis, rapidly progressive nephritis, nephrotic syndrome, IgA nephropathy, lupus nephritis, hepatitis B-related nephritis, vasculitic renal injury, hypertensive renal injury, diabetic nephropathy, tumor-related renal injury, hereditary nephropathy and tubulointerstitial lesions. He is especially good at non-dialysis treatment and management of lipid kidney injury, diabetic nephropathy and chronic kidney disease (CKD) and prevention and treatment of blood purification complications.